Innovative Medicines Initiative

Provides +1M € in subsidies for research and development within:

About Innovative Medicines Initiative

With support from the Innovative Medicines Initiative, you will be able to conduct international research for the development of new and efficient medical treatments. The initiative aims at strengthening Europe’s competitiveness through collaborations between stakeholders such as the biotech and pharma industry, governmental institutions, patient associations, and research institutions. The IMI offers funding opportunities for large companies as well as SMEs.

The Innovative Medicines Initiative is supporting a number of research topics. Overall, IMI aims to deliver:

  • A 30% better success rate in clinical trials of priority medicines identified by the WHO
  • Clinical proof of concept in immunological, respiratory, neurological and neurodegenerative diseases in just five years
  • New and approved diagnostic markers for four of these diseases and at least two new medicines which could either be new antibiotics or new therapies for Alzheimer’s disease

For 2014-2024, the IMI has a budget of 3.3 billion euro. It is financed by the EU and the industry organisation EFPIA. 

Possibilities with the Innovative Medicines Initiative

Companies can receive funding covering 75% of project cost related to R&D while other costs (e.g. management and training) can receive coverage of 100%. 

IMI's strategiske agenda har følgende fokusområder:

  • Target validation and biomarker research (efficacy and safety);
  • Adoption of innovative clinical trial paradigms;
  • Innovative medicines;
  • Patient-tailored adherence programmes.

The calls are 2-stage, initiated with an expression of interest from the consortium. Based on expert evaluation, IMI will invite selected consortias to apply in phase 2. 

Requirements for the Innovative Medicines Initiative

There are three primary requirements for a project to be eligible for funding from the Innovative Medicines Initiative:

  • Project period of 3-5 years
  • Large market potential or socioeconomic impact – min EUR 100M over five years.
  • Specific demands for the consortia depends on the research topic, but the funding option focuses greatly on the establishments of public-private partnerships and demands the inclusion of a number of stakeholders such as biotech companies, SMEs, governmental institutions, research institutions, NGOs, and institutions affecting medical requirements (e.g. HTA)

Upcoming deadlines

Below are the upcoming deadlines for Innovative Medicines Initiative. Expect 1-2 months for the proposal writing process.


The topic of this call is: Ebola and other filoviral haemorrhagic fevers (Ebola+) programme: future outbreaks. 

This call is the second call under the Ebola+ programme. It provides an opportunity to capture emerging scientific advances and to progress those rapidly into health care interventions. Projects funded under this call should ensure fast development, uptake and/or wide deployment of sustainable innovative solutions that will result in an increased readiness to respond to future outbreaks.

Can your project get funding from Innovative Medicines Initiative?

Let us contact you to discuss your possibilities within Innovative Medicines Initiative

Can your project get funding?

We can tell you if your project is suited for public funding. Tell us a little bit about your project we can help you identify the funding potential.

Tell us about your project

or call (+45) 61 60 75 08

We help you succeed

We help companies obtain public funding by converting good projects to well-prepared applications.

Our services cover the entire application process:

Identifying funding opportunities
We identifying your best funding opportunities
Planning and scoping your project
We plan and scope your project to meet demands
Writing the successful application
We write the application that increases your chance of success